Compare Weibo Corp (WB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Weibo Corp vs GeneDx Holdings Corp — how do they compare? Weibo Corp trades at $6.54 (market cap $1.56B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and Weibo Corp pays a 9.47% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Weibo Corp for 102 Days and GeneDx Holdings Corp for 19 Days on average.
| WB | WGS | |
|---|---|---|
Market Cap | $1.56B | $2.02B |
Volume | 812,503 | 734,640 |
Sector | Media | Health |
52-Week High | $12.37 | $167.51 |
52-Week Low | $6.33 | $34.51 |
Typical Hold Time | 102 Days | 19 Days |
Enterprise Value | $786.69M | $2.05B |
Dividend Yield | 9.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Weibo (WB) trades at $6.44, down 0.62% with a bearish technical outlook. The stock shows attractive valuation metrics with P/E of 5.32 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins. Recent Q2 2026 earnings beat expectations with $0.38 EPS, though Q4 2025 and Q1 2026 missed. Cash flow trends show volatility, with 2024 net cash flow negative $694 million but improving to positive $408 million in 2025. Analyst sentiment is mixed with 40.91% buy ratings amid concerns about user growth stagnation.
WB presents as a deep-value opportunity with compelling valuation multiples but faces headwinds from declining user metrics and advertising revenue challenges. The risk-reward profile favors patient investors willing to tolerate near-term volatility for potential multiple expansion, though competitive pressures and regulatory uncertainties in China's social media landscape require careful monitoring.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
